This inventor holds 1 USPTO granted patent. Top assignee: Washington University. Active years: 2007.
Company Filing History:
Years Active: 2007
Title: Kenneth P. Murphy: Innovator in Lymphocyte Inhibition
Introduction
Kenneth P. Murphy is a notable inventor based in St. Louis, MO (US). He has made significant contributions to the field of immunology, particularly in understanding lymphocyte activity. His work has implications for therapeutic and diagnostic applications.
Latest Patents
Kenneth P. Murphy holds a patent for BTLA nucleic acids. The present invention provides a novel lymphocyte inhibitory receptor termed BTLA, which is expressed on both T and B cells. This invention identifies the B7 family member B7as interacting with BTLA to attenuate lymphocyte activity. Additionally, methods and compositions for modulating BTLA-mediated negative signaling and interfering with the interaction of BTLA and B7 for therapeutic, diagnostic, and research purposes are also provided.
Career Highlights
Kenneth P. Murphy is affiliated with Washington University, where he continues to advance research in immunology. His work has garnered attention for its potential to influence treatments for various immune-related conditions.
Collaborations
Some of his notable coworkers include Norihiko Watanabe and Theresa L. Murphy. Their collaborative efforts contribute to the ongoing research and development in the field.
Conclusion
Kenneth P. Murphy's innovative work in lymphocyte inhibition exemplifies the impact of research on therapeutic advancements. His contributions continue to shape the future of immunological studies and applications.